|
LETTER TO THE EDITOR |
|
Year : 2020 | Volume
: 15
| Issue : 3 | Page : 179-180 |
|
Significance of physiotherapy in “SARS-CoV-2/COVID-19: An Epidemic” |
|
Mandeep Kumar Jangra, Akanksha Saxena
Department of Physiotherapy, Maharishi Markandeshwar Institute of Physiotherapy and Rehabilitation, Maharishi Markandeshwar (Deemed) University, Mullana, Ambala, Haryana, India
Date of Submission | 21-Apr-2020 |
Date of Acceptance | 02-May-2020 |
Date of Web Publication | 18-Jun-2020 |
Correspondence Address: Dr. Mandeep Kumar Jangra Department of Physiotherapy, Maharishi Markandeshwar Institute of Physiotherapy and Rehabilitation, Maharishi Markandeshwar (Deemed) University, Mullana, Ambala, Haryana India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/atm.ATM_169_20
|
|
How to cite this article: Jangra MK, Saxena A. Significance of physiotherapy in “SARS-CoV-2/COVID-19: An Epidemic”. Ann Thorac Med 2020;15:179-80 |
Sir,
COVID-19 is a newly recognized disease which spread rapidly from Wuhan to other places of China as well as across the world.[1] The WHO declared COVID-19 outbreak as the sixth Public Health Emergency of International Concern on January 30, 2020. Primarily, it was labeled as “Pneumonia of unknown etiology.”[2] Later, the human coronavirus (CoV) was found as the causative agent, named as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) by the experts of the International Committee on Taxonomy of Viruses).[3] Later, on February 11, 2020, the WHO announced that the disease caused by this new CoV was a COVID-19.[2]
CoVs belong to the genus Coronavirus in the Coronaviridae (order Nidovirales) and divided into four genera, namely, alpha, beta, delta, and gamma CoV. Beta-CoV genus is further divided into four subgenra/lineages, i.e., A, B, C, and D. SARS-CoV-2 belongs to beta-CoV-B lineage and causes a serious issue to public health.[4] The first four cases of SARS-CoV-2/COVID-19 had a direct exposure to Huanan Seafood wholesale market of Wuhan.[5] The subsequent cases were not having such exposure, so human-to-human transmission has been confirmed, and transmission is reported to occur by direct contact with infected secretion or large aerosol droplets.
The most common symptom of SARS-CoV-2/COVID-19 is fever followed by cough, dyspnea, myalgia, sputum production, headache, and diarrhea. Sore throat, nausea, rhinorrhea, and vomiting may also be noted. Ground-glass opacity, bilateral lung involvement, is the most common radiological finding from computed tomography scan. It may lead to complications such as acute respiratory distress syndrome, acute cardiac injury, acute kidney injury, acute liver dysfunction, and pneumothorax.[1]
Treatment and Prevention | |  |
No specific treatment is recommended for SARS-CoV-2/COVID-19. The main focus of treatment is infection control measures, symptomatic relief, oxygen therapy, and organ support.
Physiotherapy | |  |
Physiotherapy may play a vital role in the respiratory management and rehabilitation of patients with SARS-CoV-2/COVID-19. A cardiorespiratory therapist contributes a significant role in the management of patients with confirmed/suspected SARS-CoV-2/COVID-19. Dyspnea is the common feature of this condition; inspiratory muscle training and breathing exercises may be beneficial to improve dyspnea. Physiotherapy may be indicated in patients with copious secretions that are unable to clear independently and adequately. High-risk patients who have existing comorbidities e.g. Chronic respiratory or neurological conditions should be indicated physiotherapy interventions. The practicing physiotherapist may use postural drainage and various manual/mechanical airway clearance techniques to clear the airways. Physiotherapists may assist in the positioning of patients; prone position has favorable outcomes in patients with severe respiratory distress associated with SARS-CoV-2/COVID-19. Positioning is also useful to prevent secondary complications.[6] SARS-CoV-2/COVID-19 patients in the intensive care unit (ICU) are at a high risk of ICU-acquired weakness due to mechanical ventilator support, sedation, neuromuscular blockers, or prolonged bedridden, which may lead to poor health-related quality of life.[7] Therefore, it is important to anticipate early rehabilitation to prevent or limit the ICU-acquired weakness. Physiotherapists provide exercises, early mobilization, and rehabilitation strategy in patients with SARS-CoV-2/COVID-19 to make them functionally independent at the time of discharge from hospital.[8]
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
References | |  |
1. | Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARSCoV2 pneumonia in Wuhan, China: A singlecentered, retrospective, observational study. The Lancet Respiratory Medicine 2020;8;475-81. |
2. | Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Raffaela ND. Features, evaluation and treatment coronavirus (COVID19). In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK554776/. [Last update on 2020 Mar 20]. |
3. | Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Anastasia A, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology 2020;5:536-44. |
4. | Suganthan N. Covid-19. Jaffna Med J 2019;31:3-8. |
5. | Li Q, Guan X. Early transmission dynamics in Wuhan, China, of novel coronavirus –Infected pneumonia. N Engl J Med 2020;382:1199-207. |
6. | Thomas P, Baldwin C, Bissett B, Boden I, Gosselink R, Granger CL, et al. Physiotherapy management for COVID-19 in the acute hospital setting: Recommendations to guide clinical practice. Version 1.0, published 23 March 2020. |
7. | Lee CM, Fan E. ICU-acquired weakness: What is preventing its rehabilitation in critically ill patients? BMC Med 2012;10:115. |
8. | Nordon-Craft A, Moss M, Quan D, Schenkman M. Intensive care unit-acquired weakness: Implications for physical therapist management. Phys Ther 2012;92:1494-506. |
|
|
This article has been cited by | 1 |
Sera Metabolomics Characterization of Patients at Different Stages in Wuhan Identifies Critical Biomarkers of COVID-19 |
|
| Meijia Gu, Huaqin Pan, Yuncong Yuan, Xuemin Zhou, Luojia Chen, Xingran Wang, Fang Fang, Liu Hu, Yaxuan Xie, Chao Shen | | Frontiers in Cellular and Infection Microbiology. 2022; 12 | | [Pubmed] | [DOI] | | 2 |
Rehabilitation at the Time of Pandemic: Patient Journey Recommendations |
|
| Ahmed M. Negm, Adrian Salopek, Mashal Zaide, Victoria J. Meng, Carlos Prada, Yaping Chang, Preeti Zanwar, Flavia H. Santos, Elena Philippou, Emily R. Rosario, Julie Faieta, Shanti M. Pinto, Jason R. Falvey, Amit Kumar, Timothy A. Reistetter, Vanina Dal Bello-Haas, Mohit Bhandari, Jonathan F. Bean, Patricia C. Heyn | | Frontiers in Aging Neuroscience. 2022; 14 | | [Pubmed] | [DOI] | | 3 |
Providing rehabilitation to patients recovering from
COVID-19
: A scoping review
|
|
| Marina B. Wasilewski, Stephanie R. Cimino, Kristina M. Kokorelias, Robert Simpson, Sander L. Hitzig, Lawrence Robinson | | PM&R. 2021; | | [Pubmed] | [DOI] | | 4 |
Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies |
|
| Aadil Khursheed, Vikrant Jain, Ajaz Rasool, Manzoor A. Rather, Nisar Ahmad Malik, Aabid Hussain Shalla | | Microbial Pathogenesis. 2021; 157: 104933 | | [Pubmed] | [DOI] | | 5 |
Challenges and Opportunities to Develop Diagnostics and Therapeutic Interventions for Severe Acute Respiratory Syndrome- Corona Virus 2 (SARS-COV-2) |
|
| Jaison Jeevanandam, Subhamoy Banerjee, Rajkumar Paul | | Journal of Biomedical Research & Environmental Sciences. 2020; 6(10): 219 | | [Pubmed] | [DOI] | |
|
|
 |
|
|
|
|
|
|
|
Article Access Statistics | | Viewed | 3515 | | Printed | 63 | | Emailed | 0 | | PDF Downloaded | 445 | | Comments | [Add] | | Cited by others | 5 | |
|

|